Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
165 hedge funds and large institutions have $458M invested in Esperion Therapeutics in 2022 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 58 increasing their positions, 39 reducing their positions, and 25 closing their positions.
255% more call options, than puts
Call options by funds: $50.3M | Put options by funds: $14.2M
76% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 25
49% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 39
11% more funds holding
Funds holding: 148 → 165 (+17)
8% more capital invested
Capital invested by funds: $426M → $458M (+$32.6M)
4.67% more ownership
Funds ownership: 95.15% → 99.81% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.4M |
| 3 |
BlackRock
New York
|
+$6.8M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$6.47M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$5.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.7M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$11.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.52M |
| 4 |
Walleye Capital
New York
|
-$4.68M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$4.4M |
ESPR Hedge Fund Activity: Q4 2022 in Review
165 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2022, worth a combined $458M — up 7.7% from $426M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ESPR positions and 25 closed out — a net gain of 19 holders — while 58 added to existing stakes and 39 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $18.8M. The largest seller was Deep Track Capital, cutting an estimated $11.7M.
- 165 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2022, up from 148 in Q3 2022.
- Funds reported $458M of Esperion Therapeutics stock for Q4 2022, up 7.7% quarter-over-quarter.
- 44 funds opened new Esperion Therapeutics positions in Q4 2022 and 25 closed out, a net change of +19 holders.
- The largest Esperion Therapeutics buyer in Q4 2022 was Balyasny Asset Management, an estimated $18.8M added.
- The largest Esperion Therapeutics seller in Q4 2022 was Deep Track Capital, an estimated $11.7M sold.
Based on aggregated 13F filings for Q4 2022.